Lexaria Bioscience (LEXX) Other Accumulated Expenses (2025 - 2026)
Lexaria Bioscience's (LEXX) quarterly Other Accumulated Expenses came in at $200000.0 in Q1 2026, down 86.67% quarter-over-quarter from $1.5 million in Q4 2025.
Lexaria Bioscience (LEXX) Other Accumulated Expenses (2025 - 2026) Analysis & Trends
Lexaria Bioscience has disclosed Other Accumulated Expenses across 2 years of filings, most recently posting $200000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Lexaria Bioscience | 7.63 Mn | 2.11 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 200,000.00 |
| Nov 30, 2025 | 1.50 Mn |